Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for reduction of ovarian endometrioma size
IRCT20150817023666N9Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in endometriosis and endometrioma comparing Cabergoline arm with Placebo arm (2 arms). Primary endpoint: Size of endometrioma. Started Jan 2018; status: completed.
02
Drugs
cabergoline
03
Conditions
endometriosisendometrioma
Beyond the preview
Go deeper on IRCT20150817023666N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150817023666N9.